Navigation Links
Study Shows Machine Perfusion Significantly Improves Transplant Results
Date:12/31/2008

passed 100,000," said Joseph Vassalotti, MD, Chief Medical Officer of the National Kidney Foundation. "Any new method like the one demonstrated in this study, that will help maximize the available organs and potentially reduce the need for re-transplantation, is vitally important for patients and the professionals who care for them."

More than 1.5 million people worldwide suffer from end stage renal disease, for which a kidney transplant is the preferred treatment option. With a continuing global shortage of organs for transplantation, it is important to find ways of increasing not just the number of kidneys available but also the quality of organs for transplantation to improve the long-term outcome for recipients. By improving the quantity and quality of organs for transplant, both improvements in clinical outcomes and cost savings to health systems are likely to occur.

The LifePort provides a sealed, sterile, protected environment where a physiologic solution is gently pumped through the kidney at cold temperatures to minimize damage while the organ is outside the body. The LifePort is lightweight and portable allowing organs to be perfused and evaluated from the time of recovery until transplant. It can travel unaccompanied by land or air, safely transporting the kidneys across town or between states.

About the Machine Preservation Trial

The Machine Preservation Trial was an investigator-driven study, run by an independent Scientific Steering Committee across The Netherlands, Belgium and Germany, with Eurotransplant (an international organ exchange organization) collaborating as study coordinators. The Machine Preservation trial was sponsored by Organ Recovery Systems of Chicago, USA, manufacturers of the LifePort Kidney Transporter.

About Organ Recovery Systems

Organ Recovery Systems is a division of Lifeline Scientific Inc., a Chicago-based
'/>"/>

SOURCE Organ Recovery Systems
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
2. New study indicates smallpox vaccination effective for decades
3. Cardiums InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery Study
4. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
5. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
6. Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
7. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
8. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
9. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
10. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
11. Cryoablation of Early Invasive Ductal Breast Cancer With MRI Confirmation Shows Promising Clinical Benefits, According to Study Presented at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
(Date:5/17/2013)... (PRWEB) May 17, 2013 Tooth decay is ... showing active signs of the disease. The World Health Organization ... nearly 100% of adults have cavities. What are the long-term ... is showing a strong connection between the oral bacterial imbalance ... this disease so rampant, yet it is also 100% preventable? ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... , , SOUTH PLAINFIELD, ... the initiation of a Phase 3 trial of ataluren (formerly ... mutation cystic fibrosis (nmCF). Patients with CF lack adequate ... a chloride channel necessary for normal function of the lung, ...
... , , INDIANAPOLIS, Sept. 10 ... Advanced lithium-ion battery maker EnerDel, Inc. today named Richard L. Stanley ... global manufacturing and management experience and a distinguished record of creating ... appointments designed to position EnerDel for continued success in the next ...
... , OXFORD, England, September ... Watkins as Head of the Product & Portfolio,Strategy ... Senior Advisors,and Analysts. , ... "We are,delighted to welcome Nikki to PharmaVentures. Our ...
Cached Biology Technology:PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6Lithium-Ion Battery Maker Names New President 2Lithium-Ion Battery Maker Names New President 3Lithium-Ion Battery Maker Names New President 4Lithium-Ion Battery Maker Names New President 5Lithium-Ion Battery Maker Names New President 6PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy 2
(Date:5/16/2013)... NEW YORK , May 16, 2013 ... market research report is available in its ... Market Forecast & Opportunities, 2018 ... data protection and old security practises such ... driven the growth of biometric technologies in ...
(Date:5/15/2013)... gout risk, new research reveals that vitamin C, also ... levels to a clinically significant degree in patients with ... with allopurinol, appears to have a weak effect on ... the results published in the American College of Rheumatology ... Gout is an inflammatory arthritis that causes excruciating pain ...
(Date:5/15/2013)... to date to examine the efficacy of PARP inhibitor ... breast and ovarian cancer, the oral drug olaparib was ... cancers. Results of the study, led by researchers from ... Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, ... Oncology,s annual meeting in Chicago in early June (Abstract ...
Breaking Biology News(10 mins):Global Biometric Systems Market Forecast & Opportunities, 2018 2Global Biometric Systems Market Forecast & Opportunities, 2018 3Global Biometric Systems Market Forecast & Opportunities, 2018 4Global Biometric Systems Market Forecast & Opportunities, 2018 5Global Biometric Systems Market Forecast & Opportunities, 2018 6Global Biometric Systems Market Forecast & Opportunities, 2018 7Vitamin C does not lower uric acid levels in gout patients 2PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations 2
... MADISON, WI, September 29, 2008 A plot of ... 110 years of sustainable farming practices can produce similar ... In 1896, Professor J.F. Duggar at the Agricultural ... an experiment to test his theories that sustainable cotton ...
... video clip of Leonard Kleinrock showing his contributions to ... George W. Bush will award the National Medals of ... leading researchers, inventors and innovators, at a ceremony in ... a.m. on Monday, September 29, 2008. Reporters interested in ...
... that inexpensive device boosts fuel economy by up to 20 ... prices, researchers in Pennsylvania are reporting results of laboratory tests ... to a car engine,s fuel injector can boost gas mileage ... precious miles per gallon, they say. Their study is scheduled ...
Cached Biology News:Experiment demonstrates 110 years of sustainable agriculture 28 National Medals of Science awardees to be honored at gala, then the White House 28 National Medals of Science awardees to be honored at gala, then the White House 38 National Medals of Science awardees to be honored at gala, then the White House 48 National Medals of Science awardees to be honored at gala, then the White House 58 National Medals of Science awardees to be honored at gala, then the White House 68 National Medals of Science awardees to be honored at gala, then the White House 78 National Medals of Science awardees to be honored at gala, then the White House 8American Chemical Society's Weekly PressPac -- Sept. 24, 2008 2American Chemical Society's Weekly PressPac -- Sept. 24, 2008 3American Chemical Society's Weekly PressPac -- Sept. 24, 2008 4American Chemical Society's Weekly PressPac -- Sept. 24, 2008 5American Chemical Society's Weekly PressPac -- Sept. 24, 2008 6American Chemical Society's Weekly PressPac -- Sept. 24, 2008 7American Chemical Society's Weekly PressPac -- Sept. 24, 2008 8
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... is a G1 cyclin required for G1-phase ... a proto-oncogene. cyclin D2 can phosphorylate ... Species Reactivity: Human, Mouse, and Rat. ... is particularly well suited for neutralization of ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
Biology Products: